Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Derek Walsh · NORTHWESTERN UNIVERSITY AT CHICAGO · 2021 · $395,000 — PROJECT SUMMARY Humans have a profound, double-edged relationship with poxviruses. On one hand, the devastating effects of smallpox are unparalleled by any other pathogen in recorded history, and its eradication is a milestone in modern medicine. On the other, poxviruses are now used as highly effec…
Barton F. Haynes · DUKE UNIVERSITY · 2021 · $3,846,345 — While HIV-1 broadly neutralizing antibodies (bnAbs) provide potent protection from HIV-1, to date they have been difficult to induce in the setting of vaccination. A second type of HIV-1 envelope (Env) antibodies that are easy to induce are termed non-neutralizing antibodies (NNAbs) (because they ar…
Beth Ann Tamburini · UNIVERSITY OF COLORADO DENVER · 2021 · $227,700 — Project Summary Live attenuated vaccinations generate both humoral and cellular immune memory, accounting for much of the increased duration of protective immune memory. As increased protective immune memory to live attenuated vaccines is of critical importance, understanding the mechanisms of this …
Siyuan Ding · WASHINGTON UNIVERSITY · 2021 · $393,750 — Project Summary Rotaviruses (RVs) are a medically important human pathogen and the predominant cause of severe gastroenteritis, vomiting, and diarrhea in infants and young children worldwide. RVs are also a great model to interrogate the antiviral responses at the host mucosal surfaces. Our overall…
Shinji Makino · UNIVERSITY OF TEXAS MED BR GALVESTON · 2021 · $197,500 — Rift Valley fever Phlebovirus (RVFV), a bunyavirus, belongs to the NIAID Category A list of pathogens and the CDC list of potential bioterrorism agents. RVFV causes a disease that is endemic in sub-Saharan Africa and can emerge in explosive, mosquito-borne epidemics that decimate herds of sheep and …
Clayton C Caswell · VIRGINIA POLYTECHNIC INST AND ST UNIV · 2021 · $235,576 — Project Summary Brucella spp. are bacteria that naturally infect a variety of domesticated and wild animals leading to abortions and sterility, and these bacteria are also capable of causing debilitating human infections, which often result from human exposure to infected animals and animal product…
Beatrice H Hahn · UNIVERSITY OF PENNSYLVANIA · 2021 · $858,966 — PROJECT SUMMARY A central goal in HIV/AIDS vaccine research is the elicitation of broadly neutralizing antibodies (bNAbs). Here, we propose to leverage three recent discoveries from our groups to generate novel envelope (Env) immunogens that target the V1V2 region of the trimer…
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2021 · $3,242,006 — Neutralizing antibodies are likely to be required for an effective HIV-1 vaccine. However, few candidate vaccines efficiently elicit broadly neutralizing antibodies (bNAbs) following vaccination. Recently, the VRC working group has elicited fusion peptide-directed bNAbs in guinea pigs and non-human …
Mehul Shamal Suthar · EMORY UNIVERSITY · 2021 · $757,655 — Humoral immunity is an essential component of the immune response to flavivirus infection. Primary infection generates a robust neutralizing antibody response that mediates viral control and protection. It is becoming increasingly apparent that secondary infection with a closely related flavivirus s…
Sina A Gharib · UNIVERSITY OF WASHINGTON · 2021 · $758,287 — PROJECT SUMMARY Melioidosis, a tropical infection commonly manifesting as acute pneumonia and sepsis in humans, is caused by the Gram-negative Tier 1 select agent Burkholderia pseudomallei and represents a global public health threat with an estimated 165,000 cases and 89,000 deaths annually worldwi…
Beatrice H Hahn · UNIVERSITY OF PENNSYLVANIA · 2021 · $802,998 — PROJECT SUMMARY Studying Natural SIV Reservoirs and Human Zoonotic Risk, we discovered in the last funding period that certain strains of SIV infecting Old World monkeys and African apes share unexpected antigenic cross- reactivity with HIV-1 in the functionally important V1V2 region of the envelope…
Galit Alter · MASSACHUSETTS GENERAL HOSPITAL · 2021 · $348,242 — Abstract The robust protection conferred by emerging EUA approved SARS-CoV-2 vaccines represents a critical milestone in COVID-19 vaccine development. However, the emergence of variants has inspired renewed concern related to the protective efficacy of currently approved vaccines, which lose neutra…
David M Allman · UNIVERSITY OF PENNSYLVANIA · 2021 · $243,750 — Project summary Plasma cells that secrete antibodies against self-antigens pose a considerable threat to human health. Moreover, because many plasma cells are exceptionally long-lived, strategies are needed to deplete long-lived plasma cells (LLPCs) that secrete pathogenic antibodies. This project c…
Robbie B Mailliard · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2021 · $788,164 — ABSTRACT The CDC recommends that persons living with HIV (PWH) be vaccinated against SARS-CoV-2. However, there are minimal scientific data to support this important public health principle in relation to ongoing immune dysfunction and chronic comorbidities and the persistent HIV reservoir in antire…
Daniel Pearce Depledge · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2021 · $562,370 — 7. PROJECT SUMMARY / ABSTRACT Chemical modification of mRNA provides a powerful means to dynamically alter gene expression in eukaryotes via epitranscriptomic changes. In particular, methylation of adenosine at the N6 position (m6A) constitutes the most widespread internal base modification to mRNA.…
Emily K. Moser · UNIVERSITY OF FLORIDA · 2021 · $162,000 — PROJECT SUMMARY/ABSTRACT The NIH estimates that up to 23.5 million Americans suffer from autoimmune disease, driven in large part by germinal center (GC)-derived pathologic autoantibodies. GC B cells undergo iterative rounds of somatic hypermutation of B cell receptor (BCR) genes, and selection bas…
BRUNO DE BEZERRIL ANDRADE · VANDERBILT UNIVERSITY MEDICAL CENTER · 2021 · $695,679 — PROJECT SUMMARY Recent studies from our group have reported a peripheral blood correlate of risk (COR) transcriptional signature that identified individuals with incipient (asymptomatic) TB who progressed to active (symptomatic) TB disease within 12 months. We have also identified human genetic poly…
Clarence Buddy Creech · VANDERBILT UNIVERSITY MEDICAL CENTER · 2021 · $614,901 — Program Director/Principal Investigator (Last, First, Middle): Creech, Clarence B Supplement Abstract Phase 1, Open-Label, Randomized Study of the Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults This project supports specific aims 2…
Genevieve Giny Fouda Amou ou · DUKE UNIVERSITY · 2021 · $854,272 — Abstract As of March 2021, SARS-CoV-2 has caused more than 50 million infections and 2 million deaths, constituting an unprecedented pandemic in the modern world. While infected individuals rapidly develop IgG responses against the viral Spike after infection, some studies have indicated that indivi…
Peter B. Gilbert · FRED HUTCHINSON CANCER RESEARCH CENTER · 2021 · $2,034,708 — Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of the COVID-19 vaccine trial entitled “A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequen…